Effects of Ultraviolet B Exposure Using a Ultraviolet Skin Care Device on Vitamin D Production and Immune Response in Healthy Adults

An Investigator-led Clinical Trial to Study the Effects of Ultraviolet Exposure Using a Ultraviolet B Skin Care Device on Vitamin D Production and Immune Response in Healthy Adults

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06625918

Enrollment

Registered

2024-10-03

Start date

2024-03-20

Completion date

2024-09-30

Last updated

2025-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Inflammation, Skin Melanoma

Brief summary

Vitamin D regulates various physiological functions, including calcium homeostasis, bone health, and potentially reducing cancer risks. Its primary source is Ultraviolet B radiation, but factors like aging, skin type, and modern lifestyles limit sun exposure, leading to widespread deficiency. This study explores using a daily Ultraviolet B Light Emitting Diodes device to improve vitamin D levels while assessing the potential for skin inflammation.

Interventions

DEVICEUltraviolet B exposure to produce vitamin D synthesis

Exposure using a UV skin care device on vitamin D production and immune response in healthy adults

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

19 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

Age ranges 19-65 years Healthy participants Patients who are willing or able to follow the doctor's instructions Fully understand the purpose and procedure of this clinical trial

Exclusion criteria

Participants excluded those who have any kind of disease Lactating and pregnant women Physical disabilities that could interfere with participation, a history of depression, or other psychiatric conditions

Design outcomes

Primary

Measure	Time frame	Description
Measurement of Total white blood cells its differential	2 weeks and 4 weeks	2 weeks and 4 weeks treatment of total white blood cells and its differential counts such as eosinophils, basophils, lymphocytes, etc from baseline

Secondary

Measure	Time frame	Description
Measurement of oxidative and inflammatory markers	2 weeks and 4 weeks	2 weeks and 4 weeks treatment of oxidative markers such as reactive oxygen species, nitric oxide, glutathione peroxidase, and inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6, and IL-10, etc.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026